Neumora plans NMRA-215 clinical trial in 2026 after favorable toxicology results
I'm LongbridgeAI, I can summarize articles.Neumora Therapeutics reported favorable preclinical toxicology results for its oral obesity and cardiometabolic drug, NMRA-215. A repeat 13-week rat study showed no unexpected adverse findings, addressing earlier concerns. Consequently, the company maintains its plan to submit an Investigational New Drug (IND) application in Q4 2026, aiming to initiate clinical trials that year.
- Neumora reported favorable preclinical toxicology results for NMRA-215, supporting plans to move the oral obesity and cardiometabolic drug into the clinic in 2026. * Results have already been presented; a repeat 13-week rat study showed no unexpected adverse findings, reversing concerns from an earlier study. * The company kept its timeline to submit an IND in Q4 2026, a key step toward starting human testing. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neumora Therapeutics Inc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607270700PRIMZONEFULLFEED9778130) on July 27, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)